Brookstone Capital Management Sab Biotherapeutics, Inc. Transaction History

Brookstone Capital Management

  • $6.01 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 09, 2023
BUY
$0.54 - $9.8 $2,856 - $51,842
5,290 Added 32.13%
21,755 $0
Q3 2022

Oct 13, 2022
SELL
$0.13 - $12.4 $409 - $39,097
-3,153 Reduced 16.07%
16,465 $13,000
Q2 2022

Jul 11, 2022
BUY
$1.11 - $3.46 $21,775 - $67,878
19,618 New
19,618 $24,000

Others Institutions Holding SABS

# of Institutions
3
Shares Held
529K
Call Options Held
0
Put Options Held
0
View Full List

About SAB Biotherapeutics, Inc.

SABS Quotes by TradingView
  • Ticker SABS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,030,900
  • Market Cap $172M
  • Description
  • SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...
More about SABS
Track This Portfolio

Track Brookstone Capital Management Portfolio

Follow Brookstone Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brookstone Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Brookstone Capital Management with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email